Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Detection of Clinically Significant Prostate Cancer by Systematic TRUS-Biopsies in a Population-Based Setting Over a 20 Year Period

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Male Circumcision Complications - A systematic review, meta-analysis and meta-regression

    Research output: Contribution to journalReviewResearchpeer-review

  2. DaBlaCa-11: Photodynamic Diagnosis in Flexible Cystoscopy-A Randomized Study With Focus on Recurrence

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Racial and Sociodemographic Differences of Semen Parameters Among US Men Undergoing a Semen Analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk of Depression After Radical Prostatectomy-A Nationwide Registry-based Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Safety and oncological outcome following radiofrequency ablation of small renal masses in a single center

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: To assess the performance of systematic TRUS-biopsies in a population-based setting to detect clinically significant PCa (csPCa) in combination with age, clinical tumor category (cT), and prostate-specific antigen (PSA) in men referred for the first biopsy.

METHODS: We identified all men referred for PCa work-up because of elevated PSA who underwent initial TRUS-biopsies in the nationwide Danish Prostate Cancer Registry (DaPCaR) between January 1st, 1995 and December 31st, 2016, in Denmark. Risk of histologic findings in initial TRUS-biopsies categorized as non-malignant, insignificant PCa, or significant PCa (csPCa). We defined csPCa as any biopsy containing Gleason score 3 + 4 or above as in the PRECISION trial. We assessed risk of csPCa with absolute risk, logistic regression model, and predicted risks.

RESULTS AND LIMITATIONS: After exclusions, our cohort included 39,886 men. The diagnostic hit rate for csPCa was 40.8 %. Men with PSA > 20 ng/mL and ≥cT2 harbor a risk >75% for finding csPCa in the first TRUS biopsy-set. Men with cT1 tumors and PSA < 20 ng/mL have a risk of non-malignant histology of at least 58%. Limitations include the high number of exclusions based on missing information.

CONCLUSION: The diagnostic accuracy of systematic TRUS-biopsies is high for men with palpable tumors and high PSA. Our data point to the fact that not all men need pre-biopsy MRI to find csPCa.

Original languageEnglish
JournalUrology
Volume155
Pages (from-to)20-25
Number of pages6
ISSN0090-4295
DOIs
Publication statusPublished - Sep 2021

    Research areas

  • Clinically significance, Pre-biopsy MRI, Prostate cancer, TRUS-biopsies

ID: 67022947